Cardiometabolic Disorders

Top Story

Alirocumab with statin reduces LDL in atherosclerotic CVD, familial hypercholesterolemia

April 26, 2018
Meeting News

Icosapent ethyl decreases triglycerides in reduced kidney function, diabetes

April 25, 2018
Icosapent ethyl reduced triglycerides and other inflammatory and atherogenic markers in patients with reduced kidney function, persistent high triglycerides and either…
Meeting News

CMHC West to offer latest knowledge in cardiometabolic health

April 24, 2018
The Cardiometabolic Health Congress is planning for the upcoming CMHC West event: Advancing Cardiometabolic Health from East to West, which will offer a forum in which…
In the Journals

Obesity without metabolic syndrome does not indicate future risk for CVD

April 23, 2018
Patients with obesity who were metabolically healthy were not necessarily at lower risk for future CVD, according to a study published in the Journal of the American
More Headlines »

Understanding and Managing a Complex Dual Dilemma: Diabetes and Dyslipidemia

This activity is supported by an educational grant from Amgen.

Patients with type 2 diabetes have increased cardiovascular risk. Inhibitors of proprotein convertase subtilisin/kexin…
More »
Meeting News

VIDEO: Changing demographics impacting prevention strategies

October 11, 2017
More »
Resource Centers
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting


What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »